Insights

CNS Market Focus Target CNS therapeutic area opportunities across psychiatric and neurological disorders in Europe and key international markets where Neuraxpharm maintains direct or partner presence, leveraging existing market access and distribution footprints.

Expanded Footprint Leverage Neuraxpharm’s multi-country direct presence and global partnerships to introduce adjacent CNS formulations, digital health solutions, and long-acting injectables through co-development or distribution partnerships.

Digital Health Capitalize on the recent EPISERAS digital health initiative and AI-powered seizure detection to position companion tech-enabled therapies, remote monitoring services, and data-driven patient support programs as a value add for payers and providers.

Strategic Collaborations Explore co-development and co-commercialization with Neuraxpharm for LAI psychiatry therapies, Parkinson’s disease treatments, and breakthrough CNS devices, aligning with their partnerships and recent product launches.

Clinical & Regulatory Edge Align with Neuraxpharm’s regulatory milestones and regional MA approvals through ZIM Labs and Pharmathen collaborations to accelerate market access for new CNS formulations and advanced therapies in Europe and beyond.

Similar companies to Neuraxpharm

Neuraxpharm Tech Stack

Neuraxpharm uses 8 technology products and services including Databricks, Power BI, Amazon Web Services, and more. Explore Neuraxpharm's tech stack below.

Media & News

Neuraxpharm's Email Address Formats

Neuraxpharm uses at least 3 email formats:
Neuraxpharm Email FormatsExamplePercentage
FLast@neuraxpharm.comJDoe@neuraxpharm.com
83%
First@neuraxpharm.comJohn@neuraxpharm.com
16%
FirstLast@neuraxpharm.comJohnDoe@neuraxpharm.com
1%

Frequently Asked Questions

What is Neuraxpharm's official website and social media links?

Minus sign iconPlus sign icon
Neuraxpharm's official website is neuraxpharm.com and has social profiles on LinkedIn.

How much revenue does Neuraxpharm generate?

Minus sign iconPlus sign icon
As of October 2026, Neuraxpharm's annual revenue is estimated to be $50M - $100M.

What is Neuraxpharm's NAICS code?

Minus sign iconPlus sign icon
Neuraxpharm's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Neuraxpharm have currently?

Minus sign iconPlus sign icon
As of October 2026, Neuraxpharm has approximately 947 employees across 5 continents, including Europe, North America and Oceania. Key team members include Ceo: J. T. D., Chief Medical Officer: V. M. S. and Chief Business Development And Innovation Officer: M. B. D. Explore Neuraxpharm's employee directory with LeadIQ.

What industry does Neuraxpharm belong to?

Minus sign iconPlus sign icon
Neuraxpharm operates in the Pharmaceutical Manufacturing industry.

What technology does Neuraxpharm use?

Minus sign iconPlus sign icon
Neuraxpharm's tech stack includes Databricks, Power BI, Amazon Web Services, Redis, Microsoft 365, Microsoft Active Directory, Smartsheet and Microsoft Teams.

What is Neuraxpharm's email format?

Minus sign iconPlus sign icon
Neuraxpharm's email format typically follows the pattern of FLast@neuraxpharm.com. Find more Neuraxpharm email formats with LeadIQ.

How much funding has Neuraxpharm raised to date?

Minus sign iconPlus sign icon
As of October 2026, Neuraxpharm has raised $15M in funding. The last funding round occurred on Oct 01, 2009.
Neuraxpharm logo

Neuraxpharm

Pharmaceutical ManufacturingCatalonia, Spain501-1000 Employees

Neuraxpharm is a European specialty pharmaceutical company that concentrates on therapies for the central nervous system, covering both psychiatric and neurological conditions. Its activities encompass the development and commercialization of CNS products, with growth driven by an active pipeline, partnerships, and acquisitions. The company maintains a direct presence in more than 20 European markets, with additional reach in two Latin American countries, one in the Middle East, and one in Australia, and it collaborates with partners in more than 50 countries globally. Much of its manufacturing occurs at Neuraxpharm Pharmaceuticals in Spain, a facility that originated as Laboratorios Lesvi. The workforce is on the order of about a thousand employees. In late 2025, Neuraxpharm announced EPISERAS, a digital health solution that leverages an AI-powered wearable to aid early detection of epileptic seizures.

Section iconCompany Overview

NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
501-1000

Section iconFunding & Financials

  • $15M

    Neuraxpharm has raised a total of $15M of funding over 5 rounds. Their latest funding round was raised on Oct 01, 2009 as a Venture Round.

  • $50M - $100M

    Neuraxpharm's revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.